DAVID, Salvatore
 Distribuzione geografica
Continente #
NA - Nord America 1.745
EU - Europa 1.431
AS - Asia 737
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
AF - Africa 1
OC - Oceania 1
Totale 3.919
Nazione #
US - Stati Uniti d'America 1.698
CN - Cina 564
IE - Irlanda 361
SE - Svezia 244
FI - Finlandia 234
IT - Italia 212
DE - Germania 165
UA - Ucraina 162
TR - Turchia 110
SG - Singapore 59
CA - Canada 46
GB - Regno Unito 23
BE - Belgio 11
FR - Francia 7
NL - Olanda 6
AE - Emirati Arabi Uniti 2
EU - Europa 2
LU - Lussemburgo 2
RU - Federazione Russa 2
AT - Austria 1
BR - Brasile 1
EG - Egitto 1
ES - Italia 1
IN - India 1
MX - Messico 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
Totale 3.919
Città #
Dublin 360
Chandler 347
Jacksonville 303
Beijing 161
Izmir 106
Ashburn 94
San Mateo 92
Nanjing 87
Dearborn 82
Princeton 77
Ann Arbor 64
Wilmington 50
Toronto 44
Hebei 42
Shenyang 39
Parma 38
Singapore 37
Jinan 34
Helsinki 31
Shanghai 26
Nanchang 22
Kunming 21
Bologna 18
Changsha 18
Tianjin 17
Bremen 16
Jiaxing 15
Woodbridge 15
Boardman 14
Des Moines 13
Los Angeles 13
New York 13
Seattle 13
Hefei 12
Brussels 11
Guangzhou 10
Genoa 9
Haikou 9
Norwalk 9
Zhengzhou 9
Chengdu 5
Duncan 5
Fuzhou 5
Hangzhou 5
Napoli 5
Ningbo 5
Rockville 5
Taiyuan 5
Auburn Hills 4
Borås 4
Falls Church 4
Houston 4
Kocaeli 4
Piacenza 4
Taizhou 4
Düsseldorf 3
Forest City 3
Fremont 3
Lanzhou 3
Monteveglio 3
Rio Saliceto 3
Acquasanta Terme 2
Baotou 2
Brescia 2
Camparada 2
Dubai 2
Faenza 2
Ferrara 2
Galatina 2
Gatteo 2
Huizen 2
Leverkusen 2
Modena 2
Mountain View 2
Rome 2
Salsomaggiore 2
Sesto San Giovanni 2
Wenzhou 2
Augusta 1
Avigliano 1
Azzano Decimo 1
Bentivoglio 1
Boston 1
Cairo 1
Cambridge 1
Canosa Di Puglia 1
Carrù 1
Castelnuovo Rangone 1
Castiglione Olona 1
Cattolica 1
Cento 1
Chaoyang 1
Chingford 1
Clymer 1
Cutrofiano 1
Dego 1
Ficarazzi 1
Frankfurt Am Main 1
Galatone 1
Genova 1
Totale 2.533
Nome #
IL PROGETTO PIRP (PREVENZIONE INSUFFICIENZA RENALE PROGRESSIVA) DELLA REGIONE EMILIA-ROMAGNA: ANALISI DEI RISULTATI PRELIMINARI 171
A SIMPLE APPROACH FOR ASSESSING EQUILIBRATED KT/VB2M ON A ROUTINE BASIS. 77
CALCIFICASSI ESITATA IN GUARIGIONE DOPO TERAPIA CON TIOSOLFATO 73
IMPROVEMENT OF INTRADIALYTIC TOLERANCE WITH LOW VOLUME DIALYSIS AND BICARBONATE BUFFERING OF DIALYSATE. 73
Severe acute valproic acid intoxication successfully treated with hemodiafiltration without hemoperfusion 72
REVERSIBLE ACUTE CYCLOSPORINE NEPHROTOXICITY INDUCED BY COLCHICINE ADMINISTRATION 68
HEMOFILTRATION: PREDILUTION VERSUS POSTDILUTION 66
CLINICAL POLICIES ON THE MANAGEMENT OF CHRONIC KIDNEY DISEASE PATIENTS IN ITALY 66
Albumin loss in on-line haemodiafiltration 64
CLINICAL EFFECTS OF ONLINE DIALYSATE AND INFUSION FLUIDS 64
Tolerance to ultrafiltration in hemodialysis 63
ADHERENCE OF HUMAN MONOCYTES TO HAEMODIALYSIS MEMBRANES 62
Clinical heterogeneity of hereditary coproporphyria: diagnostic usefulness of biochemical studies. Study of a familial case 61
An overview of hemodialysis and oxidant stress 59
L'emodialisi e la dialisi peritoneale 59
2-h DIALYSIS: A REALISTIC GOAL ? 59
Sarcoid granulomatous nephritis with isolated and reversible renal failure. A case report. 59
ALTERNATIVE PATHWAY ACTIVATION OF COMPLEMENT BY CULTURED HUMAN PROXIMAL TUBULAR EPITHELIAL CELLS 58
PRESENTAZIONE DI UNA FORMULA PER IL CALCOLO IMMEDIATO DEL KT/V DELLA BETA2 MICROGLOBULINA 58
Bacterial contamination of the dialysis fluid in different dialyzing machines 58
Burnout in health care providers of dialysis service in Northern Italy—a multicentre study 57
ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION INDUCES PROINFLAMMATORY ACTIVITY IN HUMAN PROXIMAL TUBULAR EPITHELIAL CELLS. 57
Identification of operational clues to dry weight prescription in hemodialysis using bioimpedance vector analysis 56
A clinical stratification tool for chronic kidney disease progression rate based on classification tree analysis 54
Dialysis strategies 53
Hemodiafiltration and high-flux hemodialysis with polyethersulfone membranes 53
HEMOFILTRATION AND HEMODIAFILTRATION REDUCEINTRADIALYTIC HYPOTENSION IN ESRD 53
Urea in Exhaled Breath Condensate of Uraemics and Patients with Chronic Airway Diseases 53
High-efficiency dialysis with PMMA dialyzers: treatment dose delivery and long-term results 52
IL REBOUND E IL KT/V EQUILIBRATO DELLA BETA2 MICROGLOBULINA NELLE DIFFERENTI TECNICHE AD ALTO FLUSSO. 52
STORIA E PRINCIPI BIOFISICI GENERALI DELLE TECNICHE CONVETTIVE 51
ROLE OF PLATELET ACTIVATING FACTOR IN HEMODIALYSIS. 51
GLUCOSE METABOLISM AND LARGER MOLECULE REMOVAL IN LONG-TERM HIGH-EFFICIENCY HEMOFILTRATION 51
Organic contamination in dialysis water: trichloroethylene as a model compound. 51
ADEQUACY OF TREATMENT OF UREMIA IN THE NINETIES 51
Preventing the epidemic of cardiovascular disease: new perspectives in extracorporeal substitutive treatment 50
BEHAVIOUR OF B2-MICROGLOBULIN REMOVAL WITH DIFFERENT DIALYSIS SCHEDULES 50
BASIC THERAPEUTIC REQUIREMENTS IN THE TREATMENT OF SEPSIS IN ACUTE RENAL FAILURE 50
Urinary soluble CD14 mediates human proximal tubular epithelial cell injury induced by LPS 50
THE HEMATOPOIETIC SYSTEM IN RENAL FAILURE 49
CYCLOSPORIN A AND DRUG INTERACTION. 49
THE SIGNIFICANCE OF THE HBeAG/ANTI HBe SYSTEM IN HEMODIALYSISPATIENTS. A MULTICENTER STUDY. 49
Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC). 49
Alterations of the cytokine network in hemodialysis 48
Long-term outcome and clinical significance of orthostatic proteinuria. 47
Aliskiren Combined with Losartan in Type 2 Diabetesand Nephropathy 47
Contribution of echotomography (ET) to transcutaneous renal needle-biopsy (RNB) and to the detection of possible complications 46
COMPARISON OF 3 AUTOMATED ASSAYS FOR C-REACTIVE PROTEIN IN END-STAGE RENAL DISEASE: CLINICAL AND EPIDEMIOLOGICAL IMPLICATIONS 46
EFFECTS OF ADD-ON FLUVASTATIN THERAPY IN PATIENTS WITH CHRONIC PROTEINURIC NEPHROPATHY ON DUAL RENIN-ANGIOTENSIN SYSTEM BLOCKADE: THE ESPLANADE TRIAL 46
THE EMILIA-ROMAGNA REGION PIRP PROGRAMME ( PREVENTION IN PROGRESSION OF PROGRESSIVE RENAL INSUFFICIENCY) 45
EFFETTI DELLA TERAPIA PROLUNGATA CON CALCITRIOLO SU FGF23 E SUL METABOLISMO CALCIO-FOSFORICO NELL’IRC. 45
Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial. 44
Interleukin-12 is synthesized by mesangial cells and stimulates platelet-activating factor synthesis, cytoskeletal reorganization, and cell shape change 44
RISULTATI DELL’ECOCARDIOGRAFIA ESOFAGEA E TRANSTORACICA IN PAZIENTI IN EMODIALISI SENZA CARDIOPATIE CLINICAMENTE RILEVANTI 43
DANGER OF UNNECESSARILY PROLONGED DIALYSIS SESSION: CARPAL TUNNEL SYNDROME 43
Determination of urinary albumin excretion in subclinical forms of glomerulonephritis by electroimmunodiffusion. 42
CORRECTION OF UREMIC ACIDOSIS BY HEMODIALYSIS 42
Disinfection in dialysis, using aldehydes. Theoretical considerations and practical use 41
THE ROLE OF PLATELET-ACTIVATING FACTOR IN THE BIOCOMPATIBILITY OF HEMODIALYSIS MEMBRANES 41
TERAPIA CON CALCIFEDIOLO NEI PAZIENTI CON CKD E DEFICIT DI VITAMINA D. 41
Immunological aspects of urinary tract infections 40
PRODUCTION OF PLATELET ACTIVATING FACTOR BY HUMAN NEUTROPHILS AFTER BACKFILTRATION OF ENDOTOXIN CONTAMINATED DIALYSATE. 40
PRE-POSTDILUTION HEMOFILTRATION 38
THE ROLE OF ADSORPTION IN 2-MICROGLOBULIN REMOVAL 38
Variable radiological lung nodule evaluation leads to divergent management recommendations 37
PREDILUTION HEMOFILTRATION. CLINICAL EXPERIENCE AND REMOVAL OF SMALL MOLECULAR WEIGHT SOLUTES 37
HEMOFILTRATION-INDUCED SERUM MODIFICATIONS IN THE PATTERN OF LARGER MOLECULES 36
ASSOCIAZIONE TRA LIVELLI DI ACIDO URICO E RISCHIO DI PROGRESSIONE DELL’INSUFFICIENZA RENALE O DI MORTE PER OGNI CAUSA 36
THE COST/BENEFIT RATIO OF RENAL REPLACEMENT THERAPY 35
QUANTIFICAZIONE DELL’EFFICIENZA DIALITICA PER L’UREA E PER LA BETA2 MICROGLOBULINA NELLE DIFFERENTI TECNICHE AD ALTO FLUSSO. 35
Renal insufficiency (RI) evolving to a definitive cure in sarcoidosic granulomatous nephritis (SGN) 35
EFFETTI A MEDIO TERMINE DEL CALCITRIOLO NEI PAZIENTI CON INSUFFICIENZA RENALE CRONICA E IPERPARATIROIDISMO LIEVE-MODERATO 33
Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial 33
TANDEM PLASMA-EXCHANGE (PE) DIALYSIS. UNA VARIANTE SEMPLIFICATA. 32
IRON-REPLETE HAEMODIALYSIS PATIENTS DO NOT REQUIRE HIGHER ERYTHROPOIETIN DOSAGES WHEN CONVERTING FROM SUBCUTANEOUS TO INTRAVENOUS ADMINISTRATION. RESULTS OF THE ITALIAN STUDY ON ERYTHROPOIETIN CONVERTING (ISEC). 32
SARCOID GRANULOMATOUS NEPHRITIS WITH ISOLATED AND REVERSIBLE RENAL FAILURE. A CASE REPORT. 32
IN VITRO AND IN VIVO BIOCOMPATIBILITY OF SUBSTITUTED CELLULOSE AND SYNTHETIC MEMBRANES 27
Totale 3.928
Categoria #
all - tutte 13.131
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.131


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020937 166 142 61 11 88 58 108 11 31 158 27 76
2020/2021404 13 64 18 2 69 1 24 1 119 7 83 3
2021/2022359 2 1 9 6 10 7 51 62 19 47 39 106
2022/20231.243 143 110 78 82 109 151 5 75 441 3 28 18
2023/2024326 29 56 12 9 37 67 0 29 9 15 25 38
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 3.928